Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Fig. 2

Luseogliflozin normalized HFDT feeding-induced hepatosteatosis and fibrosis. a–c Staining with HE, Oil red O and Sirius red, respectively. Representative photographs of each group are shown. d–f The amounts of triglyceride, cholesterol and NEFA in the livers. g mRNA levels of collagen 1, collagen 2 and TGF. All data are shown as means + SEM

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us